
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Free Report) – Stock analysts at HC Wainwright lifted their Q4 2026 earnings per share (EPS) estimates for shares of Lakewood-Amedex Biotherapeutics in a research report issued to clients and investors on Tuesday, November 17th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings of ($0.21) per share for the quarter, up from their previous forecast of ($1.44). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Lakewood-Amedex Biotherapeutics’ current full-year earnings is $1.61 per share. HC Wainwright also issued estimates for Lakewood-Amedex Biotherapeutics’ FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.92) EPS.
A number of other research firms have also commented on LABT. Wall Street Zen lowered shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.
Lakewood-Amedex Biotherapeutics Price Performance
LABT opened at $0.24 on Thursday. The stock has a fifty day moving average of $0.80 and a 200-day moving average of $5.13. Lakewood-Amedex Biotherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $98.20.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.10).
About Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.
Read More
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
